Reps. Moran and Brady call for daytime ban on ED ads

Share this article:
Reps. James Moran (D-VA) and Robert Brady (D-PA) introduced a bill, dubbed the “Families for ED Advertising Decency Act,” that would ban ED ads on radio or TV between the hours of 6 am and 10 pm—an edict that would comport, more or less, with existing guidelines of PhRMA and individual manufacturers.

Moran contends that weekend daytime sporting events are nonetheless “saturated” with ED ads, and wants to empower the FCC to fine broadcasters that air them between those hours. The bill, formally House Resolution 2175, was introduced April 29, marking the second time Moran has introduced legislation on this topic. In 2005, Moran met with PhRMA over the first bill, and was told by the trade group that the ads would be reined in, according to an Advertising Age report.

“A number of people have come up, including colleagues, and said ‘I'm fed up, I don't want my three or four-year old grandkid asking me what erectile dysfunction is all about,'" Moran told CNN yesterday, adding, “And I don't blame them.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...